Aeon biopharma announces redemption of public warrants

Irvine, calif., march 29, 2024 (globe newswire) -- aeon biopharma, inc. (nyse: aeon; aeon.ws) (“aeon” or “the company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the company will redeem all of its outstanding warrants (the “public warrants”) to purchase shares of the company's class a common stock, par value $0.0001 per share (the “common stock”), that were issued under the warrant agreement, dated february 8, 2021 (the “warrant agreement”), by and between the company and continental stock transfer & trust company, as warrant agent (the “warrant agent”), as part of the units sold in the company's initial public offering (the “ipo”), for a redemption price of $0.10 per public warrant (the “redemption price”), that remain outstanding at 5:00 p.m. new york city time on march 29, 2024 (the “redemption date”). warrants to purchase common stock that were issued under the warrant agreement in a private placement simultaneously with the ipo and still held by the initial holders thereof or their permitted transferees are not subject to this redemption.
AEON Ratings Summary
AEON Quant Ranking